37th week of 2017 patent applcation highlights part 23 |
Patent application number | Title | Published |
20170260207 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 2017-09-14 |
20170260208 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS - The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions. | 2017-09-14 |
20170260209 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2017-09-14 |
20170260210 | METHOD FOR PREPARING MARMYCIN A AND ANALOGUES THEREOF, AND ALSO USES THEREOF - The present invention relates to a method for preparing marmycin A and analogues thereof, to novel marmycin A analogues, and also to the use of these compounds as an organelle marker and in pharmacy, in particular as antibiotics, anticancer agents and antimalarials. | 2017-09-14 |
20170260211 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER - Disclosed herein are heterocyclic compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structure of Formula (I): | 2017-09-14 |
20170260212 | METAL COMPLEX AND COLOR CONVERSION FILM COMPRISING SAME - The present disclosure relates to a novel compound, a color conversion film, a backlight unit and a display device comprising the same. | 2017-09-14 |
20170260213 | NEW METAL N-AMINOGUANIDINATE COMPLEXES FOR USE IN THIN FILM FABRICATION AND CATALYSIS - The present patent application relates to new metal complexes having at least one N-aminoguanidinate ligand. The patent application further relates to the preparation of the new metal complexes and also to their use. The new metal complexes are especially suitable as precursors for the preparation of functional layers by means of gas-phase thin-film processes such as CVD, MO-CVD, MOVPE and ALD. Additionally, they are also suitable as catalysts for olefin hydroamination and for olefm polymerization. | 2017-09-14 |
20170260214 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS - Compounds of formula (I), wherein the substituents are as defined in claim | 2017-09-14 |
20170260215 | HYDROSILYLATION REACTION CATALYST - A hydrosilylation reaction catalyst prepared from: a catalyst precursor comprising a transition metal compound, excluding platinum, belonging to group 8-10 of the periodic table, e.g., iron acetate, cobalt acetate, nickel acetate, etc.; and a ligand comprising a carbine compound such as 1,3-dimesitylimidazol-2-ylidene, etc. The hydrosilylation reaction catalyst has excellent handling and storage properties. As a result of using this catalyst, a hydrosilylation reaction can be promoted under gentle conditions. | 2017-09-14 |
20170260216 | HYDROSILYLATION IRON CATALYST - A hydrosilylation iron catalyst prepared from a two-electron ligand (L) and a mononuclear, binuclear, or trinuclear complex of iron indicated by formula (1), Fe having bonds with carbon atoms included in X and the total number of Fe-carbon bonds being 2-10. As a result of using iron, the hydrosilylation iron catalyst is advantageous from a cost perspective as well as being easily synthesized. Hydrosilylation reactions can be promoted under mild conditions by using this catalyst. | 2017-09-14 |
20170260217 | METHODS FOR SYNTHESIZING METAL MESOPORPHYRINS - Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. In embodiments, a metal mesoporphyrin compound may be formed directly from hemin without isolation of any intermediates. | 2017-09-14 |
20170260218 | NANOCRYSTAL AND PREPARATION METHOD THEREOF - A nanocrystal represented by the following Formula 1 and a preparation method thereof: | 2017-09-14 |
20170260219 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS - Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R | 2017-09-14 |
20170260220 | Metathesis Catalyst - The current invention describes new metathesis catalysts, a method for their preparation and their use in metathesis reactions. | 2017-09-14 |
20170260221 | Ruthenium-Based Photolinkers and Methods of Use - The present invention provides ruthenium-based photolinker compounds, caged molecules comprising the ruthenium-based photolinker compounds, and methods of use. In certain aspects, the compositions disclosed herein comprise an active domain conjugated to a ruthenium-based photolinker, such that irradiation of the photolinker exposes the active domain. | 2017-09-14 |
20170260222 | CRYSTALLINE FORMS OF FERRIC MALTOL - There is provided polymorphs of ferric maltol. Such forms may be useful in the treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia. | 2017-09-14 |
20170260223 | ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A - Enantiomers of 1′,6′-isoneplanocin, including derivatives of the enantiomers of 1′,6′-isoneplanocin, are disclosed along with novel synthetic methods. In particular, a substituted cyclopentane epoxide is synthesized into the enantiomers of 1′,6′-isoneplanocin. Enantiomers of carbocyclic nucleoside analogs of 3-deazaneplanocin to provide D- and L-like 1′,6′-iso-3-deazaneplanocin are also disclosed. The small molecule chemotherapeutic compounds beneficially provide DNA and RNA antiviral activity, demonstrating activity towards, for example, human cytomegalovirus, measles, Ebola, norovirus, dengue, vaccinia and HBV. Compounds exhibiting reduced S-adenosylhomocysteine hydrolase inhibitory effects are disclosed and provide improved toxicity profiles in comparison to neplanocin. The invention provides improved prophylactic and/or therapeutic antiviral efficacy. | 2017-09-14 |
20170260224 | NANOPARTICLES, PROCESS FOR PREPARATION AND USE THEREOF AS CARRIER FOR AMPHIPATIC AND HYDROPHOBIC MOLECULES IN FIELDS OF MEDICINE INCLUDING CANCER TREATMENT AND FOOD RELATED COMPOUNDS - The present invention regards nanoparticles comprising a sterol and a component derived from | 2017-09-14 |
20170260225 | 3-DESOXY DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present application provides Compound 1: | 2017-09-14 |
20170260226 | 3-NITROGEN OR SULPHUR SUBSTITUTED OESTRA-1,3,5(10),16-TETRAENE AKR1C3 INHIBITORS - The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis. | 2017-09-14 |
20170260227 | C17-ALKANEDIYL AND ALKENEDIYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF - Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: | 2017-09-14 |
20170260228 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF EYE DISEASE - The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body. | 2017-09-14 |
20170260229 | REACTION PROCESS WITH MEMBRANE SEPARATION - Provided herein are processes for carrying out a chemical reaction of a substrate in a diluted reaction mixture. The processes include conducting the reaction mixture having reaction product and solvent to a filtration membrane which is permeable to the solvent but impermeable to the reaction product. Solvent which permeates the filtration membrane for dilution of the substrate feed is recycled. | 2017-09-14 |
20170260230 | COMPUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 2017-09-14 |
20170260231 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof - Inhibitors of fibroblast activation protein alpha (FAP) and Prolyl Oligopeptidase (POP) are disclosed, along with their use in various therapies related to conditions, diseases, and disorders involving abnormal cell proliferation such as malignancies and angiogenesis, and in neural disorders such as Alzheimer's disease. Stalk portions of the inhibitor molecules, and substrates of FAP and POP, are also disclosed and may be used, for example, in screening methods for identifying such inhibitors. | 2017-09-14 |
20170260232 | TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE - Tubulysin compounds of the formula (I) | 2017-09-14 |
20170260233 | PEPTIDE HAVING OSTEOCLAST DIFFERENTIATION AND ACTIVATION INHIBITION, AND USE OF SAME - A peptide which is formed from an amino acid sequence selected from the group comprising amino acid sequences of SEQ ID NO: 1 to SEQ ID NO: 3, according to the present invention, has osteoclast differentiation and activation inhibition and is highly effective for preventing or treating bone diseases related to the destruction of the bone. A peptide, according to the present invention, reduces expression of cathepsin K and TRAP related to osteoclast differentiation, inhibits nuclear translocation of NF-kB, and ultimately inhibits osteoclast differentiation. Provided is a composition, for preventing or treating bone diseases, comprising the peptide. | 2017-09-14 |
20170260234 | ALZHEIMER'S DISEASE TREATMENT METHOD - The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Aβ40 and Aβ42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease. | 2017-09-14 |
20170260235 | POLYPEPTIDE EXPRESSED IN THE STRATUM CORNEUM AND USE THEREOF - Polypeptides belonging to the family of late proteins of the cornified envelope (LCE), fragments of the polypeptide, isolated nucleotide sequences encoding the polypeptides, and cosmetic and/or pharmaceutical compositions containing such polypeptides are described. The polypeptides have cosmetic and/or therapeutic use to reinforce the barrier function of the epidermis, prevent and/or treat the signs of skin dryness and prevent and/or treat disorders of the barrier function or the weakening of the epidermis. | 2017-09-14 |
20170260236 | COMPOSITIONS FOR EXPANDING REGULATORY T CELLS (TREG), AND TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES AND CONDITIONS - Provided are compositions, including isolated, synthetic or recombinant peptides for: expanding regulatory T cells (Treg) populations; for treating or ameliorating a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities, and acute or chronic vascular inflammatory abnormalities, and methods for making and using them. Provided are immunotherapies for promoting expansion of natural, Treg to establish, or re-establish, vascular homeostasis; or, for ameliorating: a disease or condition associated with an autoimmune disease or condition; an immune-mediated vascular disorder; a disease or condition treated with intravenous immunoglobulin (WIG) therapy; a vascular coronary abnormality; an acute or a chronic vasculitis; an autoimmune inflammatory vasculitis; a T cell mediated pediatric vasculitis; Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries; atherosclerosis; preventing miscarriage in autoimmune women; rheumatoid arthritis or Juvenile Idiopathic Arthritis; a neoplastic hematological disorder, or a leukemia. | 2017-09-14 |
20170260237 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS - The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases. | 2017-09-14 |
20170260238 | New Polypeptides - The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein said first and second monomer unit search comprises an FcRn binding motif. Said FcRn binding dimer binds FcRn with higher capacity compared to said first monomer unit or second monomer unit alone. The present disclosure also relates to the use of said FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent. | 2017-09-14 |
20170260239 | MODIFIED VP1-CAPSID PROTEIN OF PARVOVIRUS B19 - The inventions relates to a modified VP1-capsid protein of parvovirus B19 having reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SEQ ID NO: 1. | 2017-09-14 |
20170260240 | BROAD SPECTRUM CONJUGATE VACCINE TO PREVENT KLEBSIELLA PNEUMONIAE AND PSEUDOMONAS AERUGINOSA INFECTIONS - The present invention is drawn to conjugates and vaccine compositions comprising a | 2017-09-14 |
20170260241 | TREATMENT OF DIABETES, TOLL-LIKE RECEPTOR 4 MODULATORS AND METHODS FOR USING THE SAME - The present invention relates to treatment of diabetes, toll-like receptor 4 (TLR-4) modulators and methods for using the same. Particularly, the present invention provides an isolated peptide from pneumolysin (PLY peptide) which is effective in treatment of diabetes. In addition, the PLY peptide of the present invention is a TLR-4 antagonist and thus can be used in the treatment of a disease or condition associated with TLR-4 activation. The present invention also provides treatment of diabetes with a TLR-4 antagonist. | 2017-09-14 |
20170260242 | METHOD FOR MODIFYING RNA BINDING PROTIEN USING PPR MOTIF - The objects of the present invention are to identify the amino acids that play a principal role for the PPR motif to act as a RNA binding unit, as well as to provide a technology that regulates the RNA binding property thereof. The present invention provides a method for altering the RNA binding property of a PPR protein having one or more, preferably 2 or more, and more preferably 2-14 PPR motifs that consist of a polypeptide with a length of 30-38 amino acids, comprising a step of substituting one or more of the 1st, 4th, 8th, 9th, and 12th amino acids in the one or more PPR motifs with a different amino acid. | 2017-09-14 |
20170260243 | CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF - Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates. | 2017-09-14 |
20170260244 | Endoplasmic Reticulum Localization Signals - The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides. | 2017-09-14 |
20170260245 | TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING AND USING THE SAME - The invention features homo-multimers, e.g., homo-trimers, of TNFSF or TNF-like ligand muteins in which each TNFSF ligand or TNF-like ligand mutein monomer contains at least one cysteine residue substitution or insertion that promotes the formation of a disulfide bond with a cysteine residue on a neighboring TNFSF or TNF-like ligand mutein monomer. The invention features methods of producing such TNFSF and TNF-like ligand muteins, pharmaceutical compositions containing such muteins, and methods of using such muteins in cancer immunotherapy, in treating autoimmune and neurological diseases, and in reducing or eliminating the complications and risks of rejection in organ transplantation or tissue or organ repair or regeneration. | 2017-09-14 |
20170260246 | CARCINOMA HOMING PEPTIDE (CHP), ITS ANALOGS, AND METHODS OF USING - A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models. CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments. | 2017-09-14 |
20170260247 | Method For Synthesizing Degarelix - The present invention relates to the field of medicinal synthesis, and discloses a method for synthesizing degarelix. The method of the present invention as a whole divides the synthesis of degarelix into two parts from amino acids at positions 5 and 6, employs proper protective groups in part of the protected amino acids therein, and finally uses in association with a specific acidolysis agent to complete the whole synthesis process. In the present invention, a proper synthesizing scheme is selected, and adaptive protective group and acidolysis agent are selected, so that the overall synthesis process is optimized, the purity of degarelix is significantly improved with a higer total yield, and the production of the toxic hydantoin degradation product is avoided. | 2017-09-14 |
20170260248 | STABILIZED INSULINOTROPIC PEPTIDES AND METHODS OF USE - The present invention provides stably crosslinked insulinotropic polypeptides having superior and unexpected benefits in the treatment of conditions involving abnormal glucose homeostasis, e.g., type 2 diabetes and conditions relating to type 2 diabetes. Such benefits include, but are not limited to, extended polypeptide half-life, enhanced alpha-helicity, improved thermal stability and protease resistance, increased functional activity and pharmacologic properties, improved bioavailability when administered by any route, and improved bioavailability and gastrointestinal absorption when delivered orally, as compared to the corresponding unmodified polypeptides. The invention also provides compositions for administering the polypeptides of the invention, as well as methods for preparing and evaluating the polypeptides of the invention. | 2017-09-14 |
20170260249 | Uterine cancer treatments - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2017-09-14 |
20170260250 | MUTATIONS IN THE EXTRACELLULAR DOMAIN III OF EPIDERMAL GROWTH FACTOR RECEPTOR GENE - The invention relates to new identified mutations in the epidermal growth factor receptor gene, leading to amino acidic changes which highly correlate with the resistance to a therapy regimen comprising cetuximab. The invention includes peptide sequences and primers to detect the mutations, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer. | 2017-09-14 |
20170260251 | ECOTIN VARIANTS - Ecotin variants and their use in treating viral hemorrhagic fever are described. Described herein are methods for treating systemic inflammatory response syndrome or viral hemorrahagic fever by administering an ecotin polypeptide. Described herein is a polypeptide comprising the amino acid sequence of any of SEQ ID NOs: 2-9 and 11-18. Also described: is a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 11-18 preceded by a methionine; a polypeptide comprising the amino acid sequence of any of SEQ ID NO: 11 -18 with up to 5 single amino acid changes or deletions provided that the polypeptide does not comprise the amino acid sequence of SEQ ID NO: 10. | 2017-09-14 |
20170260252 | PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS - Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules. | 2017-09-14 |
20170260253 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES - Cysteine engineered antibodies comprising a free cysteine amino acid in the heavy chain or light chain are prepared by mutagenizing a nucleic acid sequence of a parent antibody and replacing one or more amino acid residues by cysteine to encode the cysteine engineered antibody; expressing the cysteine engineered antibody; and isolating the cysteine engineered antibody. Certain highly reactive cysteine engineered antibodies were identified by the PHESELECTOR assay. Isolated cysteine engineered antibodies may be covalently attached to a capture label, a detection label, a drug moiety, or a solid support. | 2017-09-14 |
20170260254 | METHOD FOR PRODUCING VARIANTS HAVING AN FC WITH IMPROVED SIALYLATION - The present invention relates to a method for increasing the sialylation of an Fc fragment, including a mutation step of at least one amino acid selected from among the amino acids in positions 240 to 243, 258 to 267 and 290 to 305 of the Fc fragment, the numbering being that of the EU index or equivalent in Kabat. The present invention also relates to a method for producing a variant of a parent polypeptide including an Fc fragment, the variant having improved sialylation of the Fc fragment relatively to the parent polypeptide, which includes a mutation step of at least one amino acid selected from among the amino acids in positions 240 to 243, 258 to 267 and 290 to 305 of the Fc fragment, the numbering being that of the EU index or equivalent in Kabat. | 2017-09-14 |
20170260255 | FUSION PROTEIN AND PURIFYING METHOD - The invention relates to, inter alia, a fusion protein comprising a protein of interest and an affinity tag which binds lysozyme. Lysozyme can be used to purify, precipitate, or support the crystallization of such a fusion protein. The invention further relates to a binding agent which specifically binds a target compound, wherein the binding agent has a CDR3 region which is derived from a single-domain antibody but which does not comprise framework regions or other elements for stabilizing the CDR3 region, and wherein the binding agent binds the target compound via the CDR3 region. | 2017-09-14 |
20170260256 | MODIFIED COLOSTRUM PROTEIN AND APPLICATION THEREOF - Disclosed is a modified colostrum protein having an amino acid sequence shown in SEQ ID NO.: 1, which is generated by replacing Ile at position 33, Glu at position 101 and Arg at position 175 present in the amino acid sequence of a wild type colostrum protein shown in SEQ ID NO.: 2 respectively with Ala, Cys and Cys. | 2017-09-14 |
20170260257 | ANTIBODY COMPOSITION FOR PREVENTION OR TREATMENT OF MUTANT HEPATITIS B VIRUS INFECTION - The present invention provides an antibody that binds to the surface antigen (HBsAg) of hepatitis B virus (HBV) to neutralize the hepatitis B virus. The surface antigen-binding site of the antibody was found to play a very important role in viral replication, and when a mutation in the site occurs, viral replication is significantly inhibited, and thus at least HBV virus cannot cause a mutation in the site. | 2017-09-14 |
20170260258 | ANTIBODY BINDING SPECIFICALLY TO PRE-S1 OF HEPATITIS B VIRUS AND USE OF THE ANTIBODY - Provided are: an antibody binding specifically to a surface antigen, pre-S1, of a hepatitis B virus (HBV); a polynucleotide coating the antibody; an expression vector comprising the polynucleotide; a transformation agent comprising the expression vector; and use of the antibody in treating or preventing HBV infection and in detecting an HBV. | 2017-09-14 |
20170260259 | MONOCLONAL ANTIBODY AGAINST MURAMYL PEPTIDES - Disclosed is an isolated antibody or an antigen-binding fragment thereof The antibody is capable of binding to a muramyl peptide, or a derivative or an analog or a salt thereof. The muramyl peptide comprises muramic acid and an amino acid selected from the group consisting of alanine, isoglutamine, glutamic acid, and a salt thereof. Also disclosed are methods of producing the antibody, compositions comprising the antibody, methods of treating using the antibody, uses of the antibody, methods of detecting muramyl peptide, an assay for detecting muramyl peptide, an antibacterial agent, hybridomas and kits. | 2017-09-14 |
20170260260 | Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof. | 2017-09-14 |
20170260261 | Conditionally Active Chimeric Antigen Receptors for Modified T-Cells - This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region evolved from a wild-type protein or a domain thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the antigen specific targeting region of the wild-type protein or a domain thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the antigen specific targeting region of the wild-type protein or a domain thereof. A method for generating the chimeric antigen receptor and cytotoxic cells that express the chimeric antigen receptor are also provided. | 2017-09-14 |
20170260262 | MONOCLONAL ANTIBODY AGAINST HUMAN TAU PROTEIN - The invention relates to the monoclonal antibody 1G2, the hybridoma cell line H-1 G2 characterized by DSM ACC3248, and the epitope TPP comprising the amino acids tryptophan, proline, proline. | 2017-09-14 |
20170260263 | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE - The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or peptide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein. | 2017-09-14 |
20170260264 | ANTIBODIES AGAINST NERVE GROWTH FACTOR (NGF) WITH ENHANCED IN VIVO STABILITY - The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half-life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided. | 2017-09-14 |
20170260265 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES - The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2017-09-14 |
20170260266 | TSLP BINDING PROTEINS - The present disclosure relates to TSLP binding proteins that interact with particular residues of human full length TSLP, or contact particular regions of human full length TSLP. The invention also includes pharmaceutical compositions and medical uses of these TSLP binding proteins. | 2017-09-14 |
20170260267 | METHODS OF TREATING ATOPIC DERMATITIS WITH IL-31 MONOCLONAL ANTIBODIES - The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies. | 2017-09-14 |
20170260268 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY - The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR). | 2017-09-14 |
20170260269 | SIGNALLING SYSTEM - The present invention provides a chimeric antigen receptor (CAR) signalling system comprising; (i) a receptor component comprising an antigen binding domain, a transmembrane domain and a first binding domain; and (ii) an intracellular signalling component comprising a signalling domain and a second binding domain which specifically binds the first binding domain of the receptor component; wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain, whereas in the presence of the agent the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain. | 2017-09-14 |
20170260270 | ANTI CD84 ANTIBODIES, COMPOSITIONS COMPRISING SAME AND USES THEREOF - An isolated antibody comprising an antigen recognition domain which specifically binds CD84 and
| 2017-09-14 |
20170260271 | T Cell-Redirected Antigen-Binding Molecule For Cells Having Immunosuppression Function - It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions. | 2017-09-14 |
20170260272 | LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 ANTIBODIES AND METHODS OF USE - The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same. | 2017-09-14 |
20170260273 | ANTI-C-MET/ANTI-ANG2 BISPECIFIC ANTIBODY - An anti-c-Met/anti-Ang2 bispecific antibody, a composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method of preventing and/or treating a cancer in a subject including administering the anti-c-Met/anti-Ang2 bispecific antibody to the subject. | 2017-09-14 |
20170260274 | CONSTRUCT FOR THE DELIVERY OF A MOLECULE INTO THE CYTOPLASM OF A CELL - Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1. Further, described is the use of one or more fusogenic sequence(s) derived from dengue virus glycoprotein E for use in delivery of a therapeutic moiety, a detectable moiety, a nucleic acid molecule, preferably an siRNA, a carrier molecule, preferably a nanoparticle, a liposome and a viral vector into the cytoplasm of a cell. | 2017-09-14 |
20170260275 | MYOSTATIN OR ACTIVIN ANTAGONISTS FOR THE TREATMENT OF SARCOPENIA - The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function. | 2017-09-14 |
20170260276 | TREATMENT FOR RHEUMATOID ARTHRITIS - Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab. | 2017-09-14 |
20170260277 | CD123-Specific Chimeric Antigen Receptor Redirected T Cells and Methods of Their Use - A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4/CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0×10 | 2017-09-14 |
20170260278 | METHODS OF INHIBITING PATHOLOGICAL ANGIOGENESIS WITH DOPPEL-TARGETING MOLECULES - Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described. | 2017-09-14 |
20170260279 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD - The present invention relates to anti-human OX40L antibodies, new medical uses and methods. | 2017-09-14 |
20170260280 | Antibodies that Bind to OX40 and Their Uses - The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6. | 2017-09-14 |
20170260281 | ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOF - Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells. | 2017-09-14 |
20170260282 | GITR Antibodies, Methods, and Uses - Provided herein are antibodies that specifically bind to GITR. Also described are related polynucleotides capable of encoding the provided GITR-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to enhance an immune response in a subject against cancer. | 2017-09-14 |
20170260283 | Oral Administration of an Anti-CD20 Antibody for Treatment of Autoimmune Disease - The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject. An effective oral dose of an anti-CD20 antibody is administered to the subject. Oral administration of such antibodies as rituximab, ocrelizumab, ofatumumab, obinutuzumab, tositumomab, or ibritumomab are useful in a method of decreasing innate inflammatory cytokines, such as and TNF-a, IFN-g, IL-17, and IL-12. | 2017-09-14 |
20170260284 | Cancer-Cell-Specific Antibody, Anticancer Drug, and Cancer Testing Method - An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject. | 2017-09-14 |
20170260285 | METHODS FOR TREATING CANCER - The present invention relates to pharmaceutical compositions and methods of treating cancer in a subject, the method comprising administering to the subject a combination therapy comprising administering (1) at least one anti-cancer therapy, and (2) a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an IL-1α inhibitor, wherein the combination therapy is effective to reduce at least one symptom of the cancer in the subject. | 2017-09-14 |
20170260286 | Antigen-Binding Fusion Proteins with Modified HSP70 Domains - The invention relates to fusion proteins comprising an antigen binding domain fused with a modified heat shock 70 protein. The invention further relates to methods of using the fusion proteins to induce an immune response to antigens and to treat diseases associated with antigens. | 2017-09-14 |
20170260287 | Stable Compositions of High-Concentration Allotype-Selected Antibodies for Small-Volume Administration - Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies. | 2017-09-14 |
20170260288 | COMPOSITIONS AND METHODS FOR TUMOR TRANSDUCTION - The invention relates to cancer therapeutics, in particular, the system of making cancer cells more susceptible to effector cells by introduction of cellular therapy targets into the cancer cells. | 2017-09-14 |
20170260289 | ANTIBODIES CAPABLE OF BINDING TWO EPITOPES ON TISSUE FACTOR PATHWAY INHIBITOR (1-161) - The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy. | 2017-09-14 |
20170260290 | HUMANIZED MONOCLONAL ANTIBODY, INHIBITING THE ENZYMATIC ACTIVITY OF VASCULAR ENDOTHELIAL LIPASE - Provided is a humanized monoclonal antibody or an antibody fragment thereof that selectively inhibits the enzymatic activity of vascular endothelial lipase and pharmaceutical compositions containing the same as an active ingredient useful for the treatment of arteriosclerosis or metabolic syndrome. | 2017-09-14 |
20170260291 | CHEMICALLY-LOCKED BISPECIFIC ANTIBODIES - There is disclosed a process for forming chemically-locked bispecific or heterodimer antibodies, preferably in the IgG class, in high specificity and with high homogeneity. More specifically, there is disclosed a chemically-locked bispecific IgG class antibody having a linkage region joined together with bio-orthogonal click chemistry. | 2017-09-14 |
20170260292 | LOW AFFINITY BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES AND USES THEREOF - The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same. | 2017-09-14 |
20170260293 | MULTIVALENT ANTIGEN-BINDING PROTEINS - Multivalent antigen-binding proteins comprising two or three or four or more immunoglobulin heavy chain variable domain binding domains are provided, as are methods for making them, nucleic acid constructs, and cell lines for making them. Proteins comprising two or three or four or more different heavy chain variable domains that lack an immunoglobulin variable domain are provided. Proteins comprising two or three or four or more different heavy chain variable domains that associate with the same immunoglobulin light chain variable domain are also provided. | 2017-09-14 |
20170260294 | CELLULOSE DERIVATIVE AND RESIN COMPOSITION FOR MOLDING - A cellulose derivative having a long-chain organic group having 5 or more carbon atoms and a short-chain organic group having 4 or less carbon atoms which are introduced by use of hydroxy groups of a cellulose, and including a crystal structure derived from a cellulose derivative portion to which the short-chain organic group is linked, wherein an average number of hydroxy groups per glucose unit is of 1.0 or less. | 2017-09-14 |
20170260295 | SOLID PREPARATION CONTAINING ALKYL CELLULOSE AND METHOD FOR PRODUCING THE SAME - Provided are a solid preparation comprising an alkyl cellulose which provides excellent moldability and disintegrability even in a small amount of the alkyl cellulose, and a production method therefor. Specifically, provided are a solid preparation having an alkyl cellulose having a specific surface area by BET method of 0.5 to 10.0 m | 2017-09-14 |
20170260296 | HYPROMELLOSE ACETATE SUCCINATE, METHOD FOR PRODUCING THE SAME AND COMPOSITION CONTAINING THE SAME - Provided are hypromellose acetate succinate (HPMCAS) which exhibits high solubility and can suppress generation of undissolved materials when dissolved in a solvent; an HPMCAS-containing composition; and a method for producing the HPMCAS. More specifically, provided are HPMCAS having a ratio of 2-position MS to 3-position MS of 1.2 or less, wherein the 2-position MS means a molar substitution of hydroxypropyl group by which a hydrogen atom of a hydroxyl group on 2-position carbon of each glucose unit of the HPMCAS has been directly replaced, and the 3-position MS means a molar substitution of hydroxypropyl group by which a hydrogen atom of a hydroxyl group on 3-position carbon of each glucose unit of the HPMCAS has been directly replaced; a composition comprising the HPMCAS and a solvent; and the method for producing the HPMCAS. | 2017-09-14 |
20170260297 | RESORBABLE CELLULOSE BASED BIOMATERIAL AND IMPLANT - The present disclosure describes an implant for tissue replacement or augmentation including a resorbable non-pyrogenic porous body of irradiated oxidized cellulose, formed from a precursor reactive mixture of irradiated cellulose and an oxidizing agent, where the body forms a heterogeneous three-dimensional fibrillar network. | 2017-09-14 |
20170260298 | METHOD FOR PRODUCING FUNCTIONALIZED NANOCRYSTALLINE CELLULOSE AND FUNCTIONALIZED NANOCRYSTALLINE CELLULOSE THEREBY PRODUCED - A method for producing functionalized nanocrystalline cellulose, the method comprising the steps of providing cellulose, mixing said cellulose with a peroxide, thereby producing a reaction mixture, and heating the reaction mixture, and/or exposing the reaction mixture to UV radiation is provided. Functionalized nanocrystalline cellulose produced by this method is also provided. | 2017-09-14 |
20170260299 | Process for Preparation of a Grifola frondosa Polysaccharide F2 and Its Hypoglycemic Activity | 2017-09-14 |
20170260300 | THERMOPLASTIC RESIN AND THERMOPLASTIC RESIN COMPOSITION INCLUDING THE SAME - The present invention relates to a thermoplastic resin. In accordance with the present invention, a thermoplastic resin exhibiting superior heat resistance, gloss, and whiteness while having mechanical properties identical to or higher than those of a conventional thermoplastic resin and a thermoplastic resin composition including the same are provided. | 2017-09-14 |
20170260301 | Process for Producing Conjugated Diene Polymer - The present invention provides a process for producing a conjugated diene polymer, the process including a production step of producing a conjugated diene polymer solution containing a conjugated diene polymer and a solvent, and a devolatilization step of heating the conjugated diene polymer solution while conveying the conjugated diene polymer solution with an apparatus having rotary twin screws, thereby devolatilizing the solvent, in which a motor current value of the screw in the devolatilization step and a motor current value of the screw under no load satisfy a predetermined relational expression. | 2017-09-14 |
20170260302 | MODIFIED RUBBER, RUBBER COMPOSITION AND TIRE - The present invention provides a modified rubber (A) obtained by modifying at least one rubber selected from the group consisting of natural rubbers and synthetic rubbers with a compound represented by formula (1): | 2017-09-14 |
20170260303 | METHOD FOR PREPARING ACRYLONITRILE-BUTADIENE-STYRENE GRAFT COPOLYMER AND ACRYLONITRILE-BUTADIENE-STYRENE THERMOPLASTIC RESIN COMPRISING THE SAME - The present invention relates to a method for preparing an acrylonitrile-butadiene-styrene graft copolymer having improved impact strength, which comprises: a step of preparing diene-based rubber latex by adding an acrylate-based cross-linking agent (Step 1); and a step of inserting the same cross-linking agent with the acrylate-based cross-linking agent, an aromatic vinyl-based compound and a vinyl cyan-based compound to the diene-based rubber latex and then subjecting thereof to graft copolymerization (Step 2), an acrylonitrile-butadiene-styrene graft copolymer prepared by the method, and an acrylonitrile-butadiene-styrene thermoplastic resin comprising the same. | 2017-09-14 |
20170260304 | BORON-BRIDGED 2-INDENYL METALLOCENE COMPLEXES FOR OLEFIN POLYMERIZATION - I, II, III and IV, | 2017-09-14 |
20170260305 | LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND METHOD FOR OLIGOMERIZING OLEFINS USING THE SAME - The present invention relates to a compound represented by the chemical formula 1, a catalyst system for olefin oligomerization comprising the same, and a method for oligomerizign olefins using the same, and the catalyst system for olefin oligomerization according to the present invention has excellent catalytic activity as well as high selectivity for 1-hexene or 1-octene, thereby enabling more efficient preparation of alpha-olefins. | 2017-09-14 |
20170260306 | FLUORINATED CATALYST SUPPORTS AND CATALYST SYSTEMS - Catalyst systems and methods for making and using the same. A method for making a catalyst support includes forming a mixture of a support material and a fluoride donor. The mixture is added to a fluidized bed reactor. The mixture is fluidized to form a fluidized bed while maintaining a flow rate of a fluidizing gas of about 0.1 ft./sec at less than about 370° C. and greater than about 0.35 ft./sec at temperatures greater than about 370° C. The mixture is calcined to decompose the fluoride donor, forming a fluorinated support. | 2017-09-14 |